Evaxion A/S · NASDAQ:EVAX

Evaxion A/S — Evaxion Biotech — FY2020 Earnings Presentation

16 slides from Evaxion A/S's earnings presentation, Apr 6, 2021

  1. Slide 1: 2020 Full Year Results and Business Update

    AI-immunology™ 2 0 2 0 F u l l Y e a r R e s u l t s a n d B u s i n e s s U p d a t e A p r i l 6 , 2 0 2 1 © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2021. | 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

  3. Slide 3: Disclaimer

    Disclaimer Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of

  4. Slide 4: Business Review

    B U S I N E S S R E V I E W L A RS W E G N E R , C H I E F E X E C U T I V E O F F I C E R © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2021 | 4

  5. Slide 5: Evaxion Aspires to Become a World Leader in AI-Immunology

    Evaxion Aspires to Become a World Leader in AI-Immunology, Decoding the Human Immune System, to Develop Effective Immunotherapies Based on Deep Biological Insights Immune system Artificial Intelligence Immunotherapies ©©Evaxion Evaxion Biotech BiotechA/S. A/S.All Allrights rightsreserved reservedwor

  6. Slide 6: 2020 Results Highlights and Recent Events

    2020 Results Highlights and Recent Events ● Dosed first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 in combination with checkpoint inhibitors ● Successful U.S. IPO on Nasdaq raising $30M gross proceeds ● Appointed Marianne Søgaard previously practicing commercial, technology and co

  7. Slide 7: 2021 Plan and Priorities: Advancing a Robust Immunotherapy Pipeline

    2021 Plan and Priorities: Advancing a Robust Immunotherapy Pipeline Stage of Development Product Candidate Key Upcoming AI platform (Delivery modality) Milestone Pre-clinical Phase 1 Phase 2 Phase 3 EVX-01 (Liposomal/Peptide) First Half 2021: Metastatic Melanoma, NSCLC, Bladder Cancer 2a Phase 1/2a

  8. Slide 8: EVX-01 Phase 1/2a Clinical Trial Design

    EVX-01 Phase 1/2a Clinical Trial Design Readout anticipated in first half of 2021 Part 1: Dose escalation Objectives EVX-01 + PD-1/PD-L1 Primary: Safety and tolerability Secondary: Immunogenicity and feasibility of manufacturing Dose level 1: 500 μg total peptide, n=6 Tertiary: Objective response (O

  9. Slide 9: Preliminary Data From EVX-01 Phase 1/2a Clinical Trial

    Preliminary Data From EVX-01 Phase 1/2a Clinical Trial Key findings to date, n=5 Patients Immunogenicity • 100% of patients had reactive T cells • 80.5% of the administered neoepitopes induced reactive T cells in patients, of which 84.8% were de novo responses Clinical benefit in 3 of 5 patients • O

  10. Slide 10: EVX-02: DNA-based Immunotherapy for Adjuvant Treatment of Melanoma

    EVX-02: Our DNA-based Immunotherapy for the Adjuvant Treatment of Melanoma PIONEER-predicted neoepitopes using our DNA delivery modality lead to enhanced antitumor effects in pre-clinical mouse studies Α. Tumor Volume EVX-02 induces robust, dose- EVX-02 induces neoepitope-recognizing circulating Fol

  11. Slide 11: EVX-02 Phase 1/2a Clinical Trial Design

    EVX-02 Phase 1/2a Clinical Trial Design Preliminary data readout expected first half of 2021 Objectives Primary: Safety / tolerability and immunogenicity Part 1: Delivery modality assessed Secondary: Relapse free survival at 12 months EVX-02A (polymer) plus nivolumab, n=8 Indications Adjuvant therap

  12. Slide 12: EVX-03: Targeted DNA-based Immunotherapy for Various Cancers

    EVX-03: Our Targeted DNA-based Immunotherapy for the Treatment of Various Cancers PIONEER-predicted neoepitopes using our targeted DNA delivery modality lead to enhanced antitumor effects in preclinical mouse studies Proprietary APC targeting EVX-03 compound Antitumor effect CD4+ and CD8+ T cells Th

  13. Slide 13: Financial Review

    F I NA N C I A L R E V I E W G L E N N S . V R A N I A K , C H I E F F I NA N C I A L O F F I C E R © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2021 | 13

  14. Slide 14: Key Figures for 2020

    Key Figures for 2020 Cash at year end Operating expenses Net loss 12 18 16 16 16.6 14 15 10 14 12 9.6 8 12 Cash ($M) Cash ($M) Cash ($M) 10 11.2 10 10.8 6 8 5.8 8 6 4 6 4 4 2 2 2 0 0 0 2020 2019 2020 2019 2020 2019 • Subsequently raised $27.9M after • R&D up $2.7M as invested in • Net loss widened d

  15. Slide 15: Outlook and Upcoming Milestones

    Outlook and Upcoming Milestones Financed into 2022 beyond key inflection points and expansion of pipeline to 3 clinical assets: H1 2021 EVX-01: Phase 1/2a readout and potential decision to move into a Phase 2b H1 2021 EVX-02: Phase 1/2a readout and potential decision to move into a Phase 2b H2 2021

  16. Slide 16: Thank you! Q&A

    T h a n k yo u ! Q & A © Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2021 | 16

Evaxion Biotech — FY2020 Earnings Presentation on 6ix